{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:05:36Z","timestamp":1774883136989,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Diazoxide (DZX) remains the first-line medication for the treatment of prolonged and persistent forms of hyperinsulinemic hypoglycemia (HH). In nearly 40%\u201350% of cases of HH, the genetic mechanism is unidentified. Almost half of the infants with permanent or genetic causes are DZX sensitive, but hypersensitivity to DZX is extremely rare, and the mechanism is poorly understood. Here, we report for the first time a case of DZX hypersensitivity in a neonate with HH who inherited a novel <jats:italic>HNF1A<\/jats:italic> variant from the mother. A term, male large-for-gestational-age infant of a diabetic mother presented with early onset of severe, recurrent hypoglycemia. Critical blood samples when hypoglycemic confirmed HH. Diazoxide was initiated at conventional doses of 5 mg\/kg\/day, which resulted in hyperglycemia (blood glucose, 16.6 mmol\/L) within 48 h. Glucose infusion was rapidly weaned off. DZX was withheld and eventually stopped. Following 3 days of milk feeds alone with a normal glucose profile, suspecting a resolution of HH, he underwent a 6-h fasting study and passed. While on glucose monitoring in the hospital, he again developed hypoglycemic episodes, and the critical blood samples confirmed HH. DZX was restarted at a lower dose of 3 mg\/kg\/day, which required further down-titration to 0.7 mg\/kg\/day before steady euglycemia was obtained. No more episodes of hypo- or hyperglycemia occurred, and he passed a safety fasting study before discharge. Molecular genetic testing identified a novel <jats:italic>HNF1A<\/jats:italic> mutation in the mother\u2013child dyad, whereas the father tested negative. We concluded that the HH phenotype due to this novel <jats:italic>HNF1A<\/jats:italic> mutation can be mutation specific and require a very low dose of DZX. Clinicians should observe closely for the risk of diabetic ketoacidosis and hyperglycemic hyperosmolar state while initiating DZX therapy.<\/jats:p>","DOI":"10.3389\/fendo.2024.1471596","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T04:31:26Z","timestamp":1727929886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: A novel HNF1A variant linked to gestational diabetes, congenital hyperinsulinism, and diazoxide hypersensitivity"],"prefix":"10.3389","volume":"15","author":[{"given":"Suresh","family":"Chandran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Samuel","family":"Rajadurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80588-1","article-title":"Plasma glucose values in normal neonates: a new look","volume":"109","author":"Srinivasan","year":"1986","journal-title":"J Pediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-200920","article-title":"Delayed presentation of prolonged hyperinsulinaemic hypoglycaemia in a preterm small-for-gestational age neonate","volume":"2013","author":"Chong","year":"2013","journal-title":"BMJ Case Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj0q-2020-001296","article-title":"A feed-centric hypoglycaemia pathway ensures appropriate care escalation in at-risk infants","volume":"10","author":"Chandran","year":"2021","journal-title":"BMJ Open Qual"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.867171","article-title":"Maternal obesity-associated neonatal morbidities in early newborn period","volume":"10","author":"Kureshi","year":"2022","journal-title":"Front Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.818252","article-title":"Case report: neurodevelopment outcome in a small-for-gestational-age infant with symptomatic hyperinsulinemic hypoglycemia, gaze preference, and infantile spasms","volume":"13","author":"Chandran","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2015.04.010","article-title":"Hyperinsulinemic hypoglycemia","volume":"62","author":"Guemes","year":"2015","journal-title":"Pediatr Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2012-0224","article-title":"The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism","volume":"25","author":"Hu","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09548-7","article-title":"Hyperinsulinemic Hypoglycemia in Children and Adolescents: Recent advances in understanding of pathophysiology and management","volume":"21","author":"Guemes","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12111762","article-title":"Maturity-onset diabetes of the young: mutations, physiological consequences, and treatment options","volume":"12","author":"Younis","year":"2022","journal-title":"J Pers Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1356","article-title":"Novel Presentations of Congenital Hyperinsulinism due to Mutations in the MODY genes: HNF1A and HNF4A","volume":"97","author":"Stanescu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2020.103928","article-title":"Congenital hyperinsulinism due to mutations in HNF1A","volume":"63","author":"Yau","year":"2020","journal-title":"Eur J Med Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00320","article-title":"A novel HNF4A mutation causing three phenotypic forms of glucose dysregulation in a family","volume":"8","author":"Chandran","year":"2020","journal-title":"Front Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EDM-19-0013","article-title":"Exceptional Diazoxide Sensitivity in Hyperisnulinemic Hypoglycemia due to a Novel HNF4A mutation","volume":"2019","author":"Arya","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11892-015-0681-7","article-title":"Undiagnosed MODY: time for action","volume":"15","author":"Kleinberger","year":"2015","journal-title":"Curr Diabetes Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1799-4","article-title":"Maturity onset diabetes of the young (MODY): How many cases are we missing","volume":"53","author":"Shields","year":"2010","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1371\/journal.pmed.0040118","article-title":"Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene","volume":"4","author":"Pearson","year":"2007","journal-title":"PloS Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0833-7","article-title":"Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4alpha (HNF4A)","volume":"50","author":"Fajans","year":"2007","journal-title":"Diabetologia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12655","article-title":"Clinical heterogeneity of hyperinsulinism due to HNF1A and HNF4A mutations","volume":"19","author":"Tung","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2763","article-title":"High incidence of heterozygous ABCC8 and HNF1A mutations in czech patients with congenital hyperinsulinism","volume":"100","author":"Rozenkova","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2022.07.004","article-title":"Report of prolonged neonatal hypoglycemia in three infants of mothers with variants in HNF1A","volume":"8","author":"Cromer","year":"2022","journal-title":"AACE Clin Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.stem.2022.12.001","article-title":"An insulin hypersecretion phenotype precedes pancreatic \u03b2 cell failure in MODY3 patient-specific cells","volume":"30","author":"Hermann","year":"2023","journal-title":"Cell Stem Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10545-011-9441-2","article-title":"Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management","volume":"35","author":"Senniappan","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(64)90133-7","article-title":"Drug therapy in Leucine-Sensitive hypoglycemia","volume":"13","author":"Drash","year":"1964","journal-title":"Metabolism"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(71)80241-x","article-title":"Hyperosmolar nonketotic coma associated with diazoxide therapy for hypoglycemia","volume":"78","author":"Balsam","year":"1971","journal-title":"J Pediatr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2018-0112","article-title":"Diazoxide toxicity in a child with persistent hyperinsulinemic hypoglycemia of infancy: mixed hyperglycemic hyperosmolar coma and ketoacidosis","volume":"31","author":"Mangla","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/20420986211011338","article-title":"The danger of diazoxide in the neonatal intensive care unit","volume":"12","author":"Desai","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14991","article-title":"Low-dose diazoxide therapy in hyperinsulinaemic hypoglycaemia","volume":"100","author":"Ng","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2021-322845","article-title":"Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia","volume":"107","author":"Chandran","year":"2022","journal-title":"Arch Dis Child Fetal Neonatal Ed"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1471596\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T04:31:28Z","timestamp":1727929888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1471596\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":28,"alternative-id":["10.3389\/fendo.2024.1471596"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1471596","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"article-number":"1471596"}}